1 week Ago By ABMN Staff
Norges Bank bought a new stake in Twist Bioscience Co. ( NASDAQ:TWST – Free Report ) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 163,210 shares of the company’s stock, valued at approximately $7,584,000.
Norges Bank owned 0.27% of Twist Bioscience as of its most recent SEC filing. Other hedge funds have also recently added to or reduced their stakes in the company.
FMR LLC boosted its holdings in shares of Twist Bioscience by 6.0% in the third quarter. FMR LLC now owns 218,561 shares of the company’s stock valued at $9,875,000 after acquiring an additional 12,327 shares during the period.
Stifel Financial Corp boosted its stake in Twist Bioscience by 11.8% during the 3rd quarter. Stifel Financial Corp now owns 6,967 shares of the company’s stock worth $315,000 after purchasing an additional 734 shares during the period.
State Street Corp grew its position in Twist Bioscience by 19.9% during the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after purchasing an additional 526,028 shares during the last quarter.
Wellington Management Group LLP increased its stake in Twist Bioscience by 188.5% in the third quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock valued at $36,042,000 after purchasing an additional 521,272 shares during the period.
Finally, XTX Topco Ltd raised its holdings in shares of Twist Bioscience by 36.7% in the third quarter. XTX Topco Ltd now owns 15,518 shares of the company’s stock valued at $701,000 after buying an additional 4,169 shares during the last quarter.
Twist Bioscience Stock Down 4.9 % Shares of NASDAQ TWST opened at $35.18 on Wednesday.
The stock has a market capitalization of $2.10 billion, a price-to-earnings ratio of -10.41 and a beta of 2.
34. Twist Bioscience Co. has a 52 week low of $27.
41 and a 52 week high of $60.90. The firm has a 50-day moving average price of $42.
87 and a 200 day moving average price of $44.85. The company has a quick ratio of 4.
62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03.
Insider Transactions at Twist Bioscience In related news, CFO Adam Laponis sold 5,886 shares of Twist Bioscience stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $43.26, for a total transaction of $254,628.
36. Following the completion of the transaction, the chief financial officer now directly owns 110,096 shares in the company, valued at $4,762,752.96.
The trade was a 5.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink .
Also, CEO Emily M. Leproust sold 1,726 shares of the stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $41.
68, for a total value of $71,939.68. Following the sale, the chief executive officer now owns 660,966 shares in the company, valued at approximately $27,549,062.
88. This trade represents a 0.26 % decrease in their position.
The disclosure for this sale can be found here . Insiders sold 28,682 shares of company stock valued at $1,332,011 in the last 90 days. 3.
01% of the stock is currently owned by insiders. Analysts Set New Price Targets Several brokerages recently issued reports on TWST. JPMorgan Chase & Co.
boosted their price target on Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research report on Tuesday, February 4th.
Guggenheim set a $50.00 price target on Twist Bioscience in a research note on Friday, March 28th. Robert W.
Baird lifted their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research report on Tuesday, February 4th.
Scotiabank restated an “outperform” rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. Finally, Wolfe Research initiated coverage on shares of Twist Bioscience in a report on Friday, December 13th. They issued an “outperform” rating and a $60.
00 target price on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.
com, Twist Bioscience currently has a consensus rating of “Moderate Buy” and a consensus price target of $54.10. Read Our Latest Research Report on TWST About Twist Bioscience ( Free Report ) Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products.
The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. See Also Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Co.
( NASDAQ:TWST – Free Report ). Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter .
.
